TREATMENT OF GROUP A BETA HEMOLYTIC STREPTOCOCCAL TONSILLITIS WITH CEFUROXIME AXETIL FOR 4 DAYS - A COMPARATIVE-STUDY WITH PENICILLIN-V FOR 10 DAYS

被引：26

作者：

GEHANNO, P

CHICHE, D

机构：

[1] Service de Chirurgie maxillo-faciale, Hôpital Bichat Claude Bernard, F-75018 Paris

[2] Laboratoires Glaxo, F-75116 Paris

来源：

MEDECINE ET MALADIES INFECTIEUSES | 1991年 / 21卷

关键词：

GROUP-A BETA HEMOLYTIC STREPTOCOCCUS; PHARYNGITIS; TONSILLITIS; CEFUROXIME AXETIL; PENICILLIN-V;

D O I：

10.1016/S0399-077X(05)80477-9

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The aim of this study was to compare the eradication rate of group A beta hemolytic streptococcus (GABHS) and the clinical efficacy of cefuroxime axetil (250 mg bid for 4 days) and penicillin (1 million I.U. tid for 10 days) as treatment of tonsillitis. 170 adult patients (mean age +/- standard deviation = 27 +/- 14 years; 57 male, 113 female; 90 cefuroxime axetil, 80 penicillin V), fulfilled the inclusion criteria including the isolation of GABHS from the tonsils before treatment and provided specimens for culture in the 3 days post-treatment (D4 to D7 for cefuroxime axetil, D10 to D13 for penicillin V). The eradication rates were similar: respectively 96.3 % and 95.9 %. Clinical efficacy was 99 % for CAE and 96 % for penicillin V. Symptoms disappaered significantly faster in the cefuroxime axetil group (fever, 2.5 vs 3.6 days; sore throat, 2.6 vs 3.8 days; dysphagia, 2.6 vs 3.7 days; p < 0.0001). At follow-up visit, 5 patients in the cefuroxime axetil group had a clinical relapse versus 4 in the penicillin V group. Safety was good in the 2 groups (cefuroxime axetil, 6 adverse events; penicillin V, 8). For the treatment of GABHS tonsillitis, the eradication rate with cefuroxime axetil (4 days) is similar to that with penicillin V (10 days). Clinical symptoms resolved significantly faster in the cefuroxime axetil group.

引用

页码：66 / 70

页数：5

共 24 条

[1]

Lancet, 1, pp. 1241-1242, (1987)

[2]

Bergman, Werner, Failure of children to receive penicillin by mouth, N Eng J Med, 268, pp. 1334-1338, (1963)

[3]

Bergogne Berezin, Les céphalosporines orales. Place du céfuroxime axétil, Thérapie, 43, pp. 343-349, (1988)

[4]

Brook, The role of beta-lactamase-producing organisms in the persistence of streptococcal tonsillar infection, Rev Infect Dis, 6, pp. 601-607, (1984)

[5]

Dupuis, Ebbo, Evenous, Pappo, Efficacité et tolérance du céfuroxime axétil dans les infections des voies aériennes supérieures et de leurs cavités annexes, étude comparative au céfadroxil, Rev Laryngol, 110, pp. 123-126, (1989)

[6]

Gehanno, Pangon, Moisy, Dournon, Guedon, Akoun, Les angines. Enquête épidémiologique, Méd Mal Infect, 2, pp. 75-79, (1987)

[7]

Gooch, Higbee, Gochetto, Evans, Cefuroxime axetil and penicillin V compared in the treatment of group A beta-hemolytic streptococcal pharyngitis, Clin Ther, 9, pp. 670-677, (1987)

[8]

Griffiths, Vandenburg, Wight, Gudgeon, Kelsey, Efficacy and tolerability of cefuroxime axetil in patients with upper respiratory tract infections, Current Medical Research and Opinion, 10, pp. 555-567, (1987)

[9]

Harding, Harris, Hassani, The bioavailability and pharmacokinetics of cefuroxime from RS3 tablets of cefuroxime axetil, Proceeding of the Royal college of Physicians, pp. 62-64, (1989)

[10]

Harmon, Bellows, Swift, Levy, Yound, Statements of American Heart Association Council on rheumatic fever and congenital heart disease, JAMA, 2, pp. 141-143, (1953)

← 1 2 3 →